Diabetes care dresses made in Italy with two new technologies coming out in February. The news concerns more than three and a half million patients, 6 percent of the population, which could add another 1.5 percent that represents the given submerged and still does not know to be sick.
The numbers are in growth mainly because the form of type 1, also known as “juvenile” and with a ratio of 1 in 15 of the overall landscape, alongside the most common type 2, commonly called “food”, which manifests itself in adulthood and in most cases is conditioned by the lifestyle.
the most important innovation in this field is called Abasaglar, the first biosimilar insulin glargine approved in Europe. It is basal insulin for type 1 and for the 800,000 type 2 patients who need to go to injections. It is a pre-filled pen, the diabetic can be dosed once a day as needed, and is distributed with an educational guide, a glycemic diary, an identification card, access to instructional videos on Web platform and a call number center open every day from 8.30 to 21.30.
“in addition to the so-called intuitive device and indications to improve the relationship with the disease, the absolute novelty is the fact that we speak of a biosimilar,” says George Sixth, full professor of Internal Medicine at the University Magna Graecia of Catanzaro. It also focuses on the positive effects for the national health system: “In concrete terms it means lower costs for insulin therapy and then can invest the money saved on access to other innovative medicines. The ease of use, however, facilitates the lives of patients with type 1 already accustomed to injections and helps those with type 2 who suffer particularly to insulin, and because of this often slow. “
non-adherence to medical prescriptions is indeed a very live issue between sufferers of type 2, so as to comprise a range that goes from 30 to 60 percent of cases and thus strengthen a life expectancy of 10.5 years less than the average. It is in this analysis that you insert the second new treatment called Dulaglutide, which, as Abasaglar, is manufactured by Eli Lilly in the Sesto Fiorentino together with Boehringer Ingelheim.
Last year, the international journal “Diabetes , Obesity and Metabolism “argued that the diabetics also preferred to pills. “This drug has been very effective,” says Francesco Giorgino, Professor of Endocrinology and Metabolic Diseases at the University of Bari, and leader of the team that discovered the protein “p66shc” a new mechanism responsible for the death of insulin-producing cells , thus favoring the onset of diabetes “food.”
“Dulaglutide is useful to type 2 patients who have to abandon the oral therapy or insulin support. Since this is a weekly pen, single-dose, pre-filled and easy to use with just three steps, climbs over the fear of injections thanks to a small retractable needle. Some surveys show that it acts earlier than the other products in mono-weekly administration, with a maximum effect on blood glucose levels after the second dose. Without considering that minimizes the risk of dangerous hypoglycemia and, unlike other, even an ally in weight loss. “
No comments:
Post a Comment